Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 1.00 |
| ▸ | DRD3 | P35462 | 20/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 0.67 |
| ▸ | HTR1B | P28222 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899238 | 1.00 | DRD2 (1.00) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL5899241 | 1.00 | DRD2 (1.00) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL7854789 | 0.89 | DRD2 (1.00) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL7976525 | 0.88 | DRD2 (0.79) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL7976527 | 0.88 | DRD2 (0.79) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL7852727 | 0.87 | DRD2 (0.77) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL7843892 | 0.87 | DRD2 (0.77) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL7846242 | 0.87 | DRD2 (0.77) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL7851643 | 0.86 | DRD2 (1.00) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL7851769 | 0.86 | DRD2 (1.00) | DRD2DRD3HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785447-B2 | Use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-22 | — | — | US | claimed |
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-10-05 | — | — | US | claimed |
| US-7098214-B1 | Dopamine D3 receptor ligands or antagonists for use in the treatment of renal function disorders | ABBOTT GMBH & CO. KG (DE) | 2006-08-29 | — | — | US | claimed |
| US-6143762-A | DRUGS AS DOPAMINE ANTAGONIST PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM, PLC (GB) | 2000-11-07 | — | — | US | claimed |
| US-8785447-B2 | Use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-22 | — | — | US | disclosed |
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-10-05 | — | — | US | disclosed |
| US-7098214-B1 | Dopamine D3 receptor ligands or antagonists for use in the treatment of renal function disorders | ABBOTT GMBH & CO. KG (DE) | 2006-08-29 | — | — | US | disclosed |
| EP-0922035-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2001-02-07 | — | — | EP | disclosed |
| US-6143762-A | DRUGS AS DOPAMINE ANTAGONIST PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM, PLC (GB) | 2000-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | SLC6A3, DRD3, DRD2 | DRD2 3/4885DRD3 2/4885HTR1D 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.